Opportunities center on NPPT-coated and blended urea, nitrogen stabilizers, controlled-release products, and climate-smart formulations with emissions verification. Asia-Pacific offers strong ...
Please provide your email address to receive an email when new articles are posted on . Iptacopan received traditional FDA approval for treating adults with immunoglobulin A nephropathy. The ...
Montreal, July 13, 2026 – Novartis Pharmaceuticals Canada Inc. (“Novartis Canada”) announced today that Health Canada has granted approval for VANRAFIA TM (atrasentan tablets) for proteinuria ...
Trials of current B cell-directed therapies and an investigational inhibitor of the alternative complement pathway demonstrate proteinuria reduction in patients with IgA nephropathy. Targeting ...
The FDA has granted accelerated approval to Vera Therapeutics' Trutakna (atacicept-vymj) for reducing proteinuria in adults. The approval positions Trutakna against an increasingly crowded field that ...
Trutakna (atacicept-vymj), a first-in-class dual BAFF and APRIL inhibitor, secured FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy, supported by data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results